These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19168795)

  • 21. AKT-pathway inhibition in chronic lymphocytic leukemia reveals response relationships defined by TCL1.
    Schrader A; Popal W; Lilienthal N; Crispatzu G; Mayer P; Jones D; Hallek M; Herling M
    Curr Cancer Drug Targets; 2014; 14(8):700-12. PubMed ID: 25348018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
    Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G
    Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model.
    Lascano V; Guadagnoli M; Schot JG; Luijks DM; Guikema JE; Cameron K; Hahne M; Pals S; Slinger E; Kipps TJ; van Oers MH; Eldering E; Medema JP; Kater AP
    Blood; 2013 Dec; 122(24):3960-3. PubMed ID: 24100449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.
    Öztürk S; Paul Y; Afzal S; Gil-Farina I; Jauch A; Bruch PM; Kalter V; Hanna B; Arseni L; Roessner PM; Schmidt M; Stilgenbauer S; Dietrich S; Lichter P; Zapatka M; Seiffert M
    Leukemia; 2022 Feb; 36(2):464-475. PubMed ID: 34417556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The inhibitory receptor Siglec-G controls the severity of chronic lymphocytic leukemia.
    Röder B; Fahnenstiel H; Schäfer S; Budeus B; Dampmann M; Eichhorn M; Angermüller S; Brost C; Winkler TH; Seifert M; Nitschke L
    EMBO Rep; 2023 Aug; 24(8):e56420. PubMed ID: 37424400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.
    Balatti V; Rizzotto L; Miller C; Palamarchuk A; Fadda P; Pandolfo R; Rassenti LZ; Hertlein E; Ruppert AS; Lozanski A; Lozanski G; Kipps TJ; Byrd JC; Croce CM; Pekarsky Y
    Proc Natl Acad Sci U S A; 2015 Feb; 112(7):2169-74. PubMed ID: 25646413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia.
    Janovska P; Verner J; Kohoutek J; Bryjova L; Gregorova M; Dzimkova M; Skabrahova H; Radaszkiewicz T; Ovesna P; Vondalova Blanarova O; Nemcova T; Hoferova Z; Vasickova K; Smyckova L; Egle A; Pavlova S; Poppova L; Plevova K; Pospisilova S; Bryja V
    Blood; 2018 Mar; 131(11):1206-1218. PubMed ID: 29317454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.
    Grioni M; Brevi A; Cattaneo E; Rovida A; Bordini J; Bertilaccio MTS; Ponzoni M; Casorati G; Dellabona P; Ghia P; Bellone M; Calcinotto A
    Blood Adv; 2021 Jul; 5(14):2817-2828. PubMed ID: 34269799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Eµ-TCL1 mice.
    Kohlhas V; Hallek M; Nguyen PH
    Blood Adv; 2020 Dec; 4(24):6106-6116. PubMed ID: 33351104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development.
    Zaborsky N; Gassner FJ; Höpner JP; Schubert M; Hebenstreit D; Stark R; Asslaber D; Steiner M; Geisberger R; Greil R; Egle A
    Leukemia; 2019 Apr; 33(4):957-968. PubMed ID: 30262843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.
    Kohlhaas V; Blakemore SJ; Al-Maarri M; Nickel N; Pal M; Roth A; Hövelmeyer N; Schäfer SC; Knittel G; Lohneis P; Nikolic M; Wiederstein JL; Franitza M; Georgomonolis T; Reinart N; Herling M; Herling C; Hartmann EM; Rosenwald A; Klapper W; Büttner R; Moia R; Rossi D; Boldorini R; Gaidano G; Frenzel LP; Reinhardt HC; Brüning JC; Hallek M; Krüger M; Peifer M; Pallasch CP; Wunderlich FT
    Blood; 2021 Feb; 137(5):646-660. PubMed ID: 33538798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
    Lee-Vergés E; Hanna BS; Yazdanparast H; Rodríguez V; Rodríguez ML; Giró A; Vidal-Crespo A; Rosich L; Amador V; Aymerich M; Villamor N; Delgado J; Lichter P; Pérez-Galán P; López-Guerra M; Campo E; Seiffert M; Colomer D
    Int J Cancer; 2019 Jun; 144(11):2762-2773. PubMed ID: 30468254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.
    Longo PG; Laurenti L; Gobessi S; Sica S; Leone G; Efremov DG
    Blood; 2008 Jan; 111(2):846-55. PubMed ID: 17928528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression.
    Enzler T; Kater AP; Zhang W; Widhopf GF; Chuang HY; Lee J; Avery E; Croce CM; Karin M; Kipps TJ
    Blood; 2009 Nov; 114(20):4469-76. PubMed ID: 19755673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state.
    Herling M; Patel KA; Khalili J; Schlette E; Kobayashi R; Medeiros LJ; Jones D
    Leukemia; 2006 Feb; 20(2):280-5. PubMed ID: 16341048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.
    Pekarsky Y; Palamarchuk A; Maximov V; Efanov A; Nazaryan N; Santanam U; Rassenti L; Kipps T; Croce CM
    Proc Natl Acad Sci U S A; 2008 Dec; 105(50):19643-8. PubMed ID: 19064921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity.
    Alhakeem SS; McKenna MK; Oben KZ; Noothi SK; Rivas JR; Hildebrandt GC; Fleischman RA; Rangnekar VM; Muthusamy N; Bondada S
    J Immunol; 2018 Jun; 200(12):4180-4189. PubMed ID: 29712773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL.
    Iacovelli S; Hug E; Bennardo S; Duehren-von Minden M; Gobessi S; Rinaldi A; Suljagic M; Bilbao D; Bolasco G; Eckl-Dorna J; Niederberger V; Autore F; Sica S; Laurenti L; Wang H; Cornall RJ; Clarke SH; Croce CM; Bertoni F; Jumaa H; Efremov DG
    Blood; 2015 Mar; 125(10):1578-88. PubMed ID: 25564405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic alterations in a murine model for chronic lymphocytic leukemia.
    Chen SS; Sherman MH; Hertlein E; Johnson AJ; Teitell MA; Byrd JC; Plass C
    Cell Cycle; 2009 Nov; 8(22):3663-7. PubMed ID: 19901553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.